Bidlingmaier M - Search Results

1

A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans.

Veldhuis JD, Bidlingmaier M, Bailey J, Erickson D, Sandroni P. Veldhuis JD, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2010 Aug;95(8):3844-7. doi: 10.1210/jc.2010-0538. Epub 2010 May 5. J Clin Endocrinol Metab. 2010. PMID: 20444908 Free PMC article.

2

Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH.

Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF. Thorner MO, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 1999 Jun;84(6):2098-103. doi: 10.1210/jcem.84.6.5732. J Clin Endocrinol Metab. 1999. PMID: 10372717 Clinical Trial.

3

Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance.

Muller AF, Janssen JA, Hofland LJ, Lamberts SW, Bidlingmaier M, Strasburger CJ, van der Lely AJ. Muller AF, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2001 Feb;86(2):590-3. doi: 10.1210/jcem.86.2.7173. J Clin Endocrinol Metab. 2001. PMID: 11158013 Free article.

4

The response of molecular isoforms of growth hormone to acute exercise in trained adult males.

Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson L, Boguszewski CL, Hay J, Healy ML, Napoli R, Dall R, Rosén T, Strasburger CJ. Wallace JD, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2001 Jan;86(1):200-6. doi: 10.1210/jcem.86.1.7129. J Clin Endocrinol Metab. 2001. PMID: 11232001 Clinical Trial.

5

Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males.

Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson L, Boguszewski CL, Hay J, Boroujerdi M, Cittadini A, Dall R, Rosén T, Strasburger CJ. Wallace JD, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2001 Apr;86(4):1731-7. doi: 10.1210/jcem.86.4.7379. J Clin Endocrinol Metab. 2001. PMID: 11297610 Clinical Trial.

6

Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.

Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. Veldhuis JD, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2001 Jul;86(7):3304-10. doi: 10.1210/jcem.86.7.7656. J Clin Endocrinol Metab. 2001. PMID: 11443205 Clinical Trial.

7

Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.

Muller AF, Janssen JA, Lamberts SW, Bidlingmaier M, Strasburger CJ, Hofland L, van der Lely AJ. Muller AF, et al. Among authors: bidlingmaier m. Clin Endocrinol (Oxf). 2001 Oct;55(4):461-7. doi: 10.1046/j.1365-2265.2001.01374.x. Clin Endocrinol (Oxf). 2001. PMID: 11678828 Clinical Trial.

8

Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men.

Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ. Veldhuis JD, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2002 Dec;87(12):5737-45. doi: 10.1210/jc.2001-011885. J Clin Endocrinol Metab. 2002. PMID: 12466380 Clinical Trial.

9

Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after Box1, resulting in isolated failure of STAT 5 signal transduction.

Milward A, Metherell L, Maamra M, Barahona MJ, Wilkinson IR, Camacho-Hübner C, Savage MO, Bidlingmaier M, Clark AJ, Ross RJ, Webb SM. Milward A, et al. Among authors: bidlingmaier m. J Clin Endocrinol Metab. 2004 Mar;89(3):1259-66. doi: 10.1210/jc.2003-031418. J Clin Endocrinol Metab. 2004. PMID: 15001620

10

Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.

Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G. Colao A, et al. Among authors: bidlingmaier m. Eur J Endocrinol. 2006 Mar;154(3):467-77. doi: 10.1530/eje.1.02112. Eur J Endocrinol. 2006. PMID: 16498061

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

349 results

Search Page